Methods and compositions for eliciting an immune response against hepatitis B virus
First Claim
Patent Images
1. A method for eliciting a seroprotective immune response against hepatitis B virus (HBV) in a human subject with chronic kidney disease under a vaccination schedule, comprising:
- administering to the human subject a first, second and third dose of an immunogenic composition comprising a hepatitis B surface antigen (HBsAg) and an immunostimulatory sequence (ISS) present in the immunogenic composition in amounts effective to elicit a seroprotective immune response comprising an anti-HBsAg concentration of at least 10 mIU/mL in the subject at one month after only three doses,wherein said ISS is single stranded and consists of the nucleotide sequence of SEQ ID NO;
1, and wherein said immunogenic composition comprises from about 10 to about 20 μ
g of said HBsAg and from about 1000 to about 3000 μ
g of said ISS.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof.
-
Citations
14 Claims
-
1. A method for eliciting a seroprotective immune response against hepatitis B virus (HBV) in a human subject with chronic kidney disease under a vaccination schedule, comprising:
-
administering to the human subject a first, second and third dose of an immunogenic composition comprising a hepatitis B surface antigen (HBsAg) and an immunostimulatory sequence (ISS) present in the immunogenic composition in amounts effective to elicit a seroprotective immune response comprising an anti-HBsAg concentration of at least 10 mIU/mL in the subject at one month after only three doses, wherein said ISS is single stranded and consists of the nucleotide sequence of SEQ ID NO;
1, and wherein said immunogenic composition comprises from about 10 to about 20 μ
g of said HBsAg and from about 1000 to about 3000 μ
g of said ISS. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
2. A method for eliciting a durable immune response against hepatitis B virus (HBV) in a human subject with chronic kidney disease under a vaccination schedule, comprising:
-
administering to the human subject a first, second and third dose of an immunogenic composition comprising a hepatitis B surface antigen (HBsAg) and an immunostimulatory sequence (ISS) present in the immunogenic composition in amounts effective to elicit a durable immune response comprising an anti-HBsAg concentration of at least 100 mIU/mL in the subject at 28 weeks after only three doses, wherein said ISS is single stranded and consists of the nucleotide sequence of SEQ ID NO;
1, and wherein said immunogenic composition comprises from about 10 to about 20 μ
g of said HBsAg and from about 1000 to about 3000 μ
g of said ISS.
-
Specification